BRPI1013302A2 - novas composições para tratamento de cmt e enfermidades relacionadas - Google Patents

novas composições para tratamento de cmt e enfermidades relacionadas

Info

Publication number
BRPI1013302A2
BRPI1013302A2 BRPI1013302A BRPI1013302A BRPI1013302A2 BR PI1013302 A2 BRPI1013302 A2 BR PI1013302A2 BR PI1013302 A BRPI1013302 A BR PI1013302A BR PI1013302 A BRPI1013302 A BR PI1013302A BR PI1013302 A2 BRPI1013302 A2 BR PI1013302A2
Authority
BR
Brazil
Prior art keywords
compositions
related diseases
cmt
new
new cmt
Prior art date
Application number
BRPI1013302A
Other languages
English (en)
Inventor
Cohen Daniel
Chumakov Ilya
Nabirochkin Serguei
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of BRPI1013302A2 publication Critical patent/BRPI1013302A2/pt
Publication of BRPI1013302B1 publication Critical patent/BRPI1013302B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
BRPI1013302-0A 2009-06-02 2010-05-28 Novas composições para tratamento de cmt e enfermidades relacionadas BRPI1013302B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09305506.9 2009-06-02
EP09305506A EP2263665A1 (en) 2009-06-02 2009-06-02 New compositions for treating CMT and related disorders
PCT/EP2010/057438 WO2010139627A1 (en) 2009-06-02 2010-05-28 New compositions for treating cmt and related disorders

Publications (2)

Publication Number Publication Date
BRPI1013302A2 true BRPI1013302A2 (pt) 2018-01-09
BRPI1013302B1 BRPI1013302B1 (pt) 2022-07-12

Family

ID=41168603

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013302-0A BRPI1013302B1 (pt) 2009-06-02 2010-05-28 Novas composições para tratamento de cmt e enfermidades relacionadas

Country Status (26)

Country Link
US (4) US20120088744A1 (pt)
EP (4) EP2263665A1 (pt)
JP (1) JP5875191B2 (pt)
KR (1) KR101740336B1 (pt)
CN (2) CN104688737B (pt)
AR (1) AR077540A1 (pt)
AU (1) AU2010255802B2 (pt)
BR (1) BRPI1013302B1 (pt)
CA (1) CA2763495C (pt)
CY (1) CY1115736T1 (pt)
DK (1) DK2437742T3 (pt)
EA (1) EA024523B1 (pt)
ES (2) ES2523268T3 (pt)
HK (2) HK1206590A1 (pt)
HR (1) HRP20141009T1 (pt)
IL (1) IL216621A (pt)
MX (1) MX345287B (pt)
NZ (1) NZ596656A (pt)
PL (1) PL2437742T3 (pt)
PT (1) PT2437742E (pt)
SG (1) SG176275A1 (pt)
SI (1) SI2437742T1 (pt)
SM (1) SMT201400160B (pt)
UA (1) UA110013C2 (pt)
WO (1) WO2010139627A1 (pt)
ZA (1) ZA201109423B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
EP2263665A1 (en) * 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US9867837B2 (en) * 2011-03-01 2018-01-16 Pharnext Compositions for treating neurological disorders
SI2796132T1 (sl) 2011-03-01 2018-09-28 Pharnext Terapija nevroloških motenj, ki temelji na baklofenu in akamprozatu
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
FR2987271B1 (fr) * 2012-02-28 2017-08-18 Hra Pharma Lab Combinaison de modulateurs selectifs du recepteur a la progesterone et d'anti-inflammatoires non steroidiens
WO2014163380A1 (ko) * 2013-04-02 2014-10-09 사회복지법인 삼성생명공익재단 샤르코-마리-투스 질환 치료제의 스크리닝 방법 및 이에 이용되는 자가분화운동신경세포
CA2913331C (en) 2013-06-05 2021-08-24 Pharnext Stable oral solutions for combined api
RU2686110C1 (ru) 2013-12-13 2019-04-24 Пьер Фабр Медикамент Производное хромона в качестве антагониста дофаминового рецептора d3 для применения при лечении расстройства аутистического спектра
EP3104850A1 (en) 2014-02-11 2016-12-21 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
EA201691703A1 (ru) * 2014-02-24 2017-04-28 Фарнекст Новые композиции для лечения механических повреждений нервов
WO2016191241A1 (en) * 2015-05-27 2016-12-01 Mmc & Company Llc Dual target mitochondrial impinging pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
CN111658643B (zh) * 2020-07-31 2021-12-07 西安交通大学医学院第一附属医院 雷帕霉素在难治性Graves病中的制药应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
AU9187598A (en) * 1997-09-30 1999-04-23 Daiichi Pharmaceutical Co., Ltd. Oral preparation
WO2000020024A2 (en) 1998-10-02 2000-04-13 Celtrix Pharmaceuticals, Inc. Methods for the treatment of non-thyroid disorders
WO2002049607A2 (en) 2000-12-20 2002-06-27 Firmenich Sa Flavoured oral drug delivery system
JP3805646B2 (ja) * 2001-05-25 2006-08-02 久光メディカル株式会社 医薬液剤
CN1652752A (zh) 2002-03-14 2005-08-10 欧罗赛铁克股份有限公司 盐酸纳曲酮组合物
FR2842422B1 (fr) * 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
WO2004019938A1 (en) 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
US20050038062A1 (en) 2003-04-14 2005-02-17 Burns Lindsay H. Methods and materials for the treatment of pain comprising opioid antagonists
WO2004103263A2 (en) 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
MXPA06003392A (es) 2003-09-25 2006-06-08 Euro Celtique Sa Combinacion farmaceutica de hidrocodona y naltrexona.
CA2537029C (en) * 2003-11-26 2013-03-12 Likan Liang Micellar systems useful for delivery of lipophilic or hydrophobic compounds
FR2865648B1 (fr) 2004-02-03 2006-06-30 Philippe Perovitch Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
US20050220863A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
JP2006131545A (ja) 2004-11-05 2006-05-25 Japan Science & Technology Agency 神経因性疼痛治療剤
GB0509052D0 (en) * 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
DE102006016990A1 (de) 2006-04-11 2007-10-18 Hermann, Holger Lars, Dr. Verwendung von Baclofen und Baclofen-Derivaten zur Entzugs- und/oder Substitutionsbehandlung bei Abhängigkeit von GHB und/oder GHB-Analogen
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2117517B1 (en) 2007-01-11 2011-06-01 XenoPort, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
US20080255062A1 (en) 2007-02-13 2008-10-16 University Of Manitoba Axon regeneration from adult sensory neurons
EP2065821A1 (en) 2007-11-30 2009-06-03 Pharnext Novel disease treatment by predicting drug association
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) * 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
IT1400067B1 (it) 2010-05-21 2013-05-17 Molteni & C Spray nasale liquido contenente naltrexone a bassi dosaggi.
SI2796132T1 (sl) 2011-03-01 2018-09-28 Pharnext Terapija nevroloških motenj, ki temelji na baklofenu in akamprozatu
CA2913331C (en) 2013-06-05 2021-08-24 Pharnext Stable oral solutions for combined api
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease

Also Published As

Publication number Publication date
AR077540A1 (es) 2011-09-07
JP5875191B2 (ja) 2016-03-02
CA2763495A1 (en) 2010-12-09
CN102458387A (zh) 2012-05-16
CN102458387B (zh) 2015-01-28
SMT201400160B (it) 2015-01-15
PL2437742T3 (pl) 2015-03-31
EA024523B1 (ru) 2016-09-30
US11672796B2 (en) 2023-06-13
MX345287B (es) 2017-01-24
HRP20141009T1 (hr) 2015-01-30
JP2012528818A (ja) 2012-11-15
EP2823817A1 (en) 2015-01-14
ES2523268T3 (es) 2014-11-24
MX2011012817A (es) 2011-12-16
PT2437742E (pt) 2014-11-04
AU2010255802A1 (en) 2011-12-22
IL216621A (en) 2016-05-31
KR101740336B1 (ko) 2017-06-08
HK1206590A1 (en) 2016-01-15
CA2763495C (en) 2018-06-26
EP3246025A1 (en) 2017-11-22
ZA201109423B (en) 2012-09-26
NZ596656A (en) 2013-08-30
EA201101686A1 (ru) 2012-06-29
EP2437742A1 (en) 2012-04-11
ES2641191T3 (es) 2017-11-08
CN104688737A (zh) 2015-06-10
CY1115736T1 (el) 2017-01-25
UA110013C2 (uk) 2015-11-10
WO2010139627A1 (en) 2010-12-09
HK1170150A1 (en) 2013-02-22
US9427436B1 (en) 2016-08-30
EP2437742B1 (en) 2014-08-06
EP2823817B1 (en) 2017-06-21
US20210322402A1 (en) 2021-10-21
DK2437742T3 (da) 2014-11-03
CN104688737B (zh) 2019-11-08
KR20120027353A (ko) 2012-03-21
BRPI1013302B1 (pt) 2022-07-12
AU2010255802B2 (en) 2014-08-14
US20180250290A1 (en) 2018-09-06
SG176275A1 (en) 2012-01-30
IL216621A0 (en) 2012-02-29
EP2263665A1 (en) 2010-12-22
SI2437742T1 (sl) 2015-02-27
US10905686B2 (en) 2021-02-02
US20160263104A1 (en) 2016-09-15
US20120088744A1 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
BRPI1013302A2 (pt) novas composições para tratamento de cmt e enfermidades relacionadas
BRPI1012525A2 (pt) composições de nanopatículas isentas de príons e métodos para sua fabricação
BRPI1011587A2 (pt) compostos e composições terapèuticas
SMT201700050B (it) Composizioni anestetiche termogelificanti
DK3078664T3 (da) Antiparasitiske dihydroazol-sammensætninger
FR2942627B1 (fr) Composition de graisse
DK3403654T3 (da) Oralt administrerede kortikosteroidsammensætninger
BRPI1007025A2 (pt) composições esteroidais
BR112012004176A2 (pt) implemento para cuidado oral
DOP2011000396A (es) Composiciones novedosas
UY33161A (es) Composiciones plaguicidas
BRPI1014543A2 (pt) composições pesticidas
BRPI1008366A2 (pt) Composições pesticidas
BR112013016207A2 (pt) composições para cuidados orais
BRPI1012539A2 (pt) composições farmacêuticas
BRPI1008326A2 (pt) Composições e métodos para controlar nanatódeos
FI20096058A0 (fi) Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä
BRPI1010690A2 (pt) composições
IT1394400B1 (it) Composizioni farmaceutiche
BRPI1009446A2 (pt) Composições compreendendo monatina e cálcio
BRPI1008323A2 (pt) Composições pesticidas
FI20125393L (fi) Sisäkkäin sopivien komponenttien purkaminen
BRPI1007196A2 (pt) profármacos e derivado de espiroindolinona
BR112012001340A2 (pt) composições farmacêuticas
FR2952291B3 (fr) Grill

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/05/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.